News
IDYA
39.85
+2.13%
0.83
IDEAYA Biosciences Has Selected Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-small Cell Lung Cancer, Based On The Adverse Event Profile And Preliminary Clinical Efficacy
Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC. The most sensitive tumor type to be treated with the monotherapy. Over 100,000 global annual incidence of squamousNSCLC in the United States.
Benzinga · 3d ago
IDEAYA BIOSCIENCES ANNOUNCES SELECTION OF MOVE-FORWARD PHASE 2 EXPANSION DOSE FOR IDE397 MONOTHERAPY IN MTAP-DELETION SQUAMOUS NON-SMALL CELL LUNG CANCER
Reuters · 3d ago
Weekly Report: what happened at IDYA last week (0415-0419)?
Weekly Report · 3d ago
IDEAYA Biosciences (IDYA) Gets a Buy from Stifel Nicolaus
TipRanks · 6d ago
Oversold Conditions For IDEAYA Biosciences
NASDAQ · 04/18 20:34
Weekly Report: what happened at IDYA last week (0408-0412)?
Weekly Report · 04/15 09:15
Weekly Report: what happened at IDYA last week (0401-0405)?
Weekly Report · 04/08 09:16
IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/05 10:00
Weekly Report: what happened at IDYA last week (0325-0329)?
Weekly Report · 04/01 09:16
TipRanks ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
TipRanks · 03/27 10:25
Weekly Report: what happened at IDYA last week (0318-0322)?
Weekly Report · 03/25 09:16
IDEAYA Biosciences Price Target Raised to $60.00/Share From $40.00 by Citigroup
Dow Jones · 03/21 16:26
IDEAYA Biosciences Is Maintained at Buy by Citigroup
Dow Jones · 03/21 16:26
Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $60
Benzinga · 03/21 16:17
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), IDEAYA Biosciences (IDYA) and Vor Biopharma (VOR)
TipRanks · 03/21 10:20
Weekly Report: what happened at IDYA last week (0311-0315)?
Weekly Report · 03/18 09:16
Strong Buy Rating for IDEAYA Biosciences Based on Strategic Partnership and Promising Oncology Pipeline
TipRanks · 03/13 15:15
Ideaya gains after clinical trial pact with Merck
Ideaya Biosciences announces clinical trial pact with Merck. Biotech to obtain anti-PD-1 therapy Keytruda for a Phase 1 trial for its cancer candidate. Ideaya's cancer candidate is designed to target breast cancer and endometrial cancer.
Seeking Alpha · 03/12 13:29
IDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With KEYTRUDA In Endometrial Cancer
NASDAQ · 03/12 10:24
Weekly Report: what happened at IDYA last week (0304-0308)?
Weekly Report · 03/11 09:15
More
Webull provides a variety of real-time IDYA stock news. You can receive the latest news about Ideaya Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.